An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis

Hepatology

Volumn 65, Issue 4, 2017, Pages 1196-1205

  Atiq, Omair ^a   Tiro, Jasmin ^b,c   Yopp, Adam C ^a   Muffler, Adam ^a   Marrero, Jorge A ^a   Parikh, Neehar D ^a   Murphy, Caitlin ^c   McCallister, Katharine ^c   Singal, Amit G ^a,b,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN;

ADULT; ARTICLE; BIOPSY; CANCER EPIDEMIOLOGY; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; RETROSPECTIVE STUDY; SAFETY; SCREENING; THROMBOCYTOPENIA; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION; COHORT ANALYSIS; DOPPLER ULTRASONOGRAPHY; EARLY CANCER DIAGNOSIS; LIVER FUNCTION TEST; LIVER NEOPLASMS; MASS SCREENING; METABOLISM; MULTIVARIATE ANALYSIS; ODDS RATIO; PROCEDURES; PROGNOSIS; RISK ASSESSMENT;

ADULT; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, NEOPLASTIC; COHORT STUDIES; EARLY DETECTION OF CANCER; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MALE; MASS SCREENING; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; ULTRASONOGRAPHY, DOPPLER;

EID: 85007201706     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28895     Document Type: Article

References (35)

1. American Cancer Society. Global Cancer Facts & Figures, 3rd ed. Atlanta, GA: American Cancer Society; 2015
2. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014;74:2913–2921.
3. Singal AG, Marrero JA. Recent advances in the treatment of hepatocellular carcinoma. Curr Opin Gastroenterol 2010;26:189–195.
4. Bruix J, Sherman M. management of hepatocellular carcinoma: an update. Hepatology 2010;53:1–35.
5. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908–943.
6. Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med 2014;11:e1001624.
7. Kansagara D, Papak J, Pasha AS, O'Neil M, Freeman M, Relevo R, et al. Screening for hepatocellular carcinoma in chronic liver disease: a systematic review. Ann Intern Med 2014;161:261–269.
8. Harris RP, Wilt TJ, Qaseem A. A value framework for cancer screening: advice for high-value care from the American College of Physicians. Ann Intern Med 2015;162:712–717.
9. Denis B, Gendre I, Sauleau EA, Lacroute J, Perrin P. Harms of colonoscopy in a colorectal cancer screening programme with faecal occult blood test: a population-based cohort study. Dig Liver Dis 2013;45:474–480.
10. Marshall KG. Population-based fecal occult blood screening for colon cancer: will the benefits outweigh the harm? CMAJ 2000;163:545–546.
11. Forner A, Vilana R, Ayuso C, Bianchi L, Sole M, Ayuso JR, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology Jan 2008;47:97–104.
12. Sangiovanni A, Manini MA, Iavarone M, Romeo R, Forzenigo LV, Raquelli M, et al. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 2010;59:638–644.
13. Buscarini L, Fornari F, Bolondi L, Colombo P, Livraghi T, Magnolfi F, et al. Ultrasound-guided fine-needle biopsy of focal liver lesions: techniques, diagnostic accuracy and complications. A retrospective study on 2091 biopsies. J Hepatol 1990;11:344–348.
14. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology 2009;49:1017–1044.
15. Nehra MS, Ma Y, Clark C, Amarasingham R, Rockey DC, Singal AG. Use of administrative claims data for identifying patients with cirrhosis. J Clin Gastroenterol 2013;47:e50–e54.
16. Gupta S, Bent S, Kohlwes J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med 2003;139:46–50.
17. Yopp AC, Mansour JC, Beg MS, Arenas J, Trimmer C, Reddick M, et al. Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome. Ann Surg Oncol 2014;21:1287–1295.
18. Elmore JG, Barton MB, Moceri VM, Polk S, Arena PJ, Fletcher SW. Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med 1998;338:1089–1096.
19. Heleno B, Thomsen MF, Rodrigues DS, Jorgensen KJ, Brodersen J. Quantification of harms in cancer screening trials: literature review. BMJ 2013;347:f5334.
20. Singal AG, Conjeevaram HS, Volk ML, Fu S, Fontana RJ, Askari F, et al. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev 2012;21:793–799.
21. Joshi K, Mendler M, Gish R, Loomba R, Kuo A, Patton H, Kono Y. Hepatocellular carcinoma surveillance: a national survey of current practices in the USA. Dig Dis Sci 2014;59:3073–3077.
22. Dalton-Fitzgerald E, Tiro J, Kandunoori P, Halm EA, Yopp A, Singal AG. Practice patterns and attitudes of primary care providers and barriers to surveillance of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2015;13:791–798.
23. Gopal P, Yopp AC, Waljee AK, Chiang J, Nehra M, Kandunoori P, Singal AG. Factors that affect accuracy of alpha-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2014;12:870–877.
24. Sherman M. Alphafetoprotein: an obituary. J Hepatol 2001;34:603–605.
25. Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, Marrero JA. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009;30:37–47.
26. Patel N, Yopp AC, Singal AG. Diagnostic delays are common among patients wtih hepatocellular carcinoma. J Natl Compr Canc Netw 2015;13:543–549.
27. Singal AG, Yopp A, Skinner CS, Packer M, Lee WM, Tiro JA. Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review. J Gen Intern Med 2012;27:861–867.
28. Di Bisceglie AM, Sterling RK, Chung RT, Everhart J, Dienstag JL, Bonkovsky HL, et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol 2005;43:434–441.
29. El-Serag HB, Kanwal F, Davila JA, Kramer J, Richardson P. A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis. Gastroenterology 2014;146:1249–1255.
30. Del Poggio P, Olmi S, Ciccarese F, Di Marco M, Rapaccini GL, Benvegnu L, Borzio F, et al. Factors that affect efficacy of ultrasound surveillance for early-stage hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2014;12:1927–1933.
31. Simmons O, Fetzer DT, Yokoo T, Marrero JA, Yopp A, Kono Y, et al. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. Alimentary Pharmacology and Therapeutics 2016 November 8. doi: 10.1111/apt.13841. [Epub ahead of print]
32. Singal AG, Nehra M, Adams-Huet B, Yopp AC, Tiro JA, Marrero JA, et al. Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastroenterol 2013;108:425–432.
33. Rich N, Singal AG. Hepatocellular carcinoma tumour markers: current role and expectations. Best Pract Res Clin Gastroenterol 2014;28:843–853.
34. Singal AG, Li X, Tiro JA, Kandunoori P, Adams-Huet B, Nehra MS, Yopp A. Racial, social, and clinical determinants of hepatocellular carcinoma surveillance. Am J Med 2015;128:90e1–90e7.
35. Davila JA, Morgan RO, Richardson PA, Du XL, McGlynn KA, El_Serag HB. Utilization of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology 2010;52:132–141.